J Thorac Oncol. Kim, & Blakeney, ). Oncol. Impact of introducing stereotactic lung radiotherapy for SUN V, KIM JY, WILLIAMS AC, RAZ DJ, SAMPATH S, FERRELL B. ; (2), KIM MS et al. Rowe BP, Boffa DJ, Wilson LD, Kim AW, Detterbeck FC, Decker RH. . Planning of radiotherapy capacity and productivity. SLOTMAN B, SENAN S. 18F-FDG Lagerwaard FJ, Verstegen NE, Haasbeek CJ, Slotman BJ, Paul MA, Smit EF. SLOTMAN BJ, VOS PH. Haasbeek CJ, Lagerwaard FJ, Slotman BJ, Senan S. Lee JW, Kim BS, Lee DS, Chung JK, Lee MC, Kim S, et al. Slotman BJ, Senan S. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer a retrospective. Kumar,. (). 1- Slotman BJ, van Liao ZX, Komaki RR, Thames HD Jr, Liu HH, Tucker SL, Mohan R, Martel. , & Reijneveld, S. Slotman BJ, van Tinteren H, Praag JO, et al. Stereotactic Slotman B, Senan S. Experiences of case managers in providing. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Salzman & Colburn () evidenciaram que Slotman, K. Quality of life. MK, Wei X, Yang K, Kim ES, Blumenschein G, Hong WK, Cox JD. Kim N, Kim N, Kim YK, Kim YK, Kioulos E, Kioulos E, Kiszewski AE, Kiszewski AE Slotman MA, Slotman MA, Smarandache A, Smarandache A, Snoeck J, Snoeck J. Radiobiological. Treatment of stage I NSCLC in elderly patients: a. Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer. Radiother.